Bristol Myers Squibb Company
NEWS
Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Shares of Ziopharm Oncology, Inc. are still sliding after the company announced it was pausing its planned Phase III trial for its lead gene therapy product designed to treat patients with recurrent glioblastoma (rGBM) as a monotherapy and in combination with an immune checkpoint inhibitor.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, such as pancreas cells to cure type 1 diabetes and failed clinical trials cast doubt on new immuno-oncology targets.
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
JOBS
IN THE PRESS